Why harmonisation is an advantage (only if you manage it properly)

Harmonisation between pharmacopoeias is one of the most underused levers in QC/QA. When applied correctly, it reduces:

• duplicate testing
• complexity of method transfer
• risk of divergent interpretations during audits
• laboratory costs and timelines

When applied incorrectly, it creates the most expensive mistake: assuming that “harmonised” means “identical” and skipping critical checks.

Contrarian insight: “Harmonised = I can stop reading the notes”

This is an outdated and risky practice.

Harmonised does not mean:

• texts are identical word for word
• there are no allowed differences
• local editions/supplements can be ignored
• governance can be skipped (training, change control, instrument qualification)

In an audit, saying “it’s harmonised” without showing how it is implemented in your QMS is equivalent to saying “we trust it”.

PDG and ICH Q4B in 2 minutes (no useless theory)

• PDG (Pharmacopoeial Discussion Group): a technical forum that has worked to harmonise mainly general chapters and several excipient monographs across USP, Ph. Eur., and JP (with evolving participation and scope).
• ICH Q4B: a framework supporting the concept of regulatory interchangeability for certain chapters/annexes—meaning: if you correctly apply this chapter in one pharmacopoeia, authorities accept equivalence with the others.

Operational QA/QC translation:
If a test is harmonised/interchangeable, you can design a single method and reduce duplication—but you must:

• verify the harmonisation status
• manage allowed differences
• document the decision in the method/SOP

Allowed differences: the hidden trap (and how to neutralise it)

Allowed differences are permitted variations that should not change the compliance decision, but may affect:

• reagent preparation (Solution R vs TS)
• units of measure or expression
• procedural details
• reporting format

Best practice I always recommend:

• include a “Compendial Equivalence Statement” section in the internal method
• list the differences and your chosen approach, with justification
• retain evidence of QA review and analyst training

Key technical terms (LSI) to control here: allowed differences, system suitability, equivalence, change control, SOP, training, deviation, CAPA, method lifecycle, data integrity (ALCOA+).

Examples of real harmonisation benefits in the laboratory

Case A: One method for multiple markets

When a general chapter is harmonised, you can:

• maintain a single SOP
• apply one instrument qualification strategy (IQ/OQ/PQ)
• manage one calculation/reporting chain in LIMS
• reduce transcription and interpretation errors

Case B: Reduced duplication at batch release

If a test is harmonised, you can apply “test once, comply many”, meaning:

• perform one test
• report the result on the CoA using consistent logic
• maintain traceability to applicable requirements

Table: What PDG/ICH harmonisation helps you rationalise (and what you must not assume)

Golden rule for QA: harmonisation ≠ exemption from change control

In audits, the most common issue I see is companies using harmonisation to simplify—but then:

• failing to update methods when a supplement changes
• not reassessing impact on LOQ/LOD or system suitability
• not updating training and documentation

Result: simplification “on paper”, risk “in reality”.

Solution: integrate into the QMS a process for:

• compendial watch
• impact assessment (QA + QC + RA)
• change control
• method updates and retraining

KEY TAKEAWAYS

• Harmonised means “equivalent in outcome”, not “identical in text”.
• Allowed differences must be managed in the internal method, not left to analyst memory.
• Harmonisation works only if it is translated into SOPs, training, LIMS, and batch release checklists.

FAQ

1) If a chapter is harmonised, can I simply use an alternative method?
Alternative methods are allowed only if validated and fit for purpose. Harmonisation facilitates unification; it does not remove the need to demonstrate suitability.

2) How do I avoid mistakes when USP and Ph. Eur. texts are similar but not identical?
By managing allowed differences in the internal method and controlling the applicable edition/supplement.

3) Does harmonisation also apply to finished product monographs?
Much less. Historically, the strongest leverage is on general chapters and excipients; product-specific monographs often retain significant differences.

If you want a complete guide with examples, checklists, and criteria to exploit PDG/ICH harmonisation without errors (and to manage USP/Ph. Eur. divergences in an audit-defensible way), you’ll find “Pharmacopoeias Compared” on guidegxp.com.